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In the absence of established therapeutic reg‑
imens, early risk stratification has been the first 
approach for the management of COVID ‑19, with 
the aim to facilitate patient allocation according 
to disease severity and available resources.5-7 Sub‑
sequently, with the improvement of the clinical 
and pathophysiological knowledge on COVID ‑19, 
research quickly focused on therapeutic strat‑
egies. With more and more robust data avail‑
able, either supporting or discouraging the use 
of what was an empiric treatment, scientific soci‑
eties could come up with new recommendations8 
and updates have been subsequently released.9 
Introduction SARS ‑CoV ‑2 was first detected 
at the end of 2019 in Wuhan, the capital city 
of Hubei Province in China. Since then, the in‑
fection has spread all over the world, leading to 
a pandemic.1,2 The disease caused by SARS ‑CoV ‑2, 
namely, COVID ‑19, has so far resulted in more 
than 4 million deaths. With very limited scientific 
and clinical knowledge about the disease, nation‑
al health systems worldwide have been put under 
enormous pressure. As a result, healthcare pro‑
viders have been overwhelmed by a multitude of 
patients with COVID ‑19 of varying severity, with‑
out access to effective treatment.3,4
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Infection with SARS ‑CoV ‑2, responsible for COVID ‑19, has spread all over the world since the beginning 
of 2020. Healthcare providers and researchers have been overwhelmed not only by the rapid diffusion 
of the disease resulting in a pandemic with more than 4 million cases of death, but also by the lack 
of therapeutic options. After more than 1 year, the knowledge on COVID ‑19 has increased thanks to 
the enormous effort of the scientific community. To date, some algorithms of management have been 
adopted. While asymptomatic or mildly symptomatic patients should receive only a symptom ‑based 
treatment and clinical monitoring when necessary, inpatients could be candidates for antiviral treatment 
due to fully symptomatic disease. Corticosteroid treatment should be limited to patients with severe 
disease, particularly those with respiratory failure or acute respiratory distress syndrome. Since the main 
clinical features of COVID ‑19 are hypoxemia and dyspnea, oxygen therapy remains the cornerstone of 
managing more severe cases. In this context, the first ‑line approach should be represented by low ‑flow 
oxygen delivery via a nasal cannula or, more frequently, via a face mask with a known fraction of inspired 
oxygen. When low ‑flow oxygen fails to significantly improve oxygen saturation, oxygen therapy using 
a high ‑flow nasal cannula is recommended. The current challenges in the treatment of COVID ‑19 include 
the need to define the role of convalescent plasma and monoclonal antibodies as well as to identify 
the optimal target and time for anticoagulation. In this review, we highlight the main aspects of these 
challenges in light of recent updates.
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The dexamethasone group showed a significantly 
lower 28 ‑day mortality rate compared with con‑
trols (23.3% vs 26.2%, respectively; RR, 0.82; 
95% CI, 0.72–0.94). However, a subgroup analy‑
sis of patients without the need for oxygen sup‑
port at the time of randomization did not dem‑
onstrate a significant difference in primary out‑
come between dexamethasone and control groups 
(17.8% vs 14.0%, respectively; RR, 1.19; 95% CI, 
0.92–1.55).16 In a subsequent meta ‑analysis eval‑
uating 1703 critically ill patients with COVID ‑19, 
the 28 ‑day mortality rate was lower in patients 
receiving corticosteroids than in those receiv‑
ing either standard of care or placebo (32% vs 
40%, respectively; summary odds ratio [OR], 0.66; 
95% CI, 0.53–0.82; P <0.001).17
It should be noted that most studies performed 
in this setting did not focus on the adverse effects 
of corticosteroid administration. However, due to 
the severity of COVID ‑19, the short ‑term mor‑
tality benefits outweighed the risks of adverse 
events. Therefore, according to the most recent 
literature, corticosteroid use should be limited to 
more severe cases (particularly patients requiring 
oxygen support), while it is not recommended in 
patients without the need for oxygen therapy.9
Antivirals Several antivirals, such as lo‑
pinavir / rito navir and darunavir, have been 
evaluated for the treatment of COVID ‑19, but 
the results of clinical trials failed to demon‑
strate their efficacy.18,19 On the other hand, rem‑
desivir showed some encouraging benefits in 
the treatment of COVID ‑19. Remdesivir is a nu‑
cleotide analogue that inhibits viral RNA–de‑
pendent RNA polymerase of coronaviruses, in‑
cluding SARS ‑CoV ‑1 and Middle East respirato‑
ry syndrome coronavirus.20 The results of a meta‑
‑analysis including almost 7000 hospitalized pa‑
tients with COVID ‑19 showed that remdesivir 
did not reduce the need for mechanical venti‑
lation or mortality when compared with stan‑
dard of care or placebo. These results were in‑
fluenced by the heterogeneity of studies includ‑
ing patients with COVID ‑19 irrespective of dis‑
ease severity. Nevertheless, remdesivir reduced 
the time to recovery from severe COVID ‑19,21 
and this beneficial effect was later confirmed by 
the SARSTer study.22 The Solidarity trial failed 
to demonstrate a significant mortality reduction 
among patients treated with remdesivir vs stan‑
dard of care. However, lower mortality was ob‑
served among patients who did not require me‑
chanical ventilation at baseline.23 In the ACTT ‑1 
(Adaptive COVID ‑19 Treatment Trial), patients 
treated with remdesivir were discharged from 
the hospital or weaned off oxygen support ear‑
lier than those treated with placebo. Moreover, 
remdesivir reduced the time to recovery among 
patients who required low ‑flow oxygen at base‑
line and who received treatment within 10 days 
from symptom onset. Yet, even this trial failed to 
demonstrate a reduction in mor tality, although 
the group of remdesivir‑treated patients who 
Nevertheless, although different treatment strat‑
egies have been proposed, the optimal care of pa‑
tients with COVID ‑19 remains controversial.10
In this short review, we provide an overview 
of the most recent evidence on the pharmaco‑
logical management of patients with COVID ‑19, 
with a focus on associated pneumonia. We also 
describe the current challenges in the treatment 
of COVID ‑19. Finally, the pros and cons of the re‑
ported therapeutic options are discussed.
Corticosteroids The rationale for the administra‑
tion of corticosteroids in patients with COVID ‑19 
is based on the pathophysiological features of 
the disease. As in other viral pneumonias (eg, 
severe acute respiratory syndrome and avian in‑
fluenza), severe inflammatory response during 
SARS ‑CoV ‑2 infection may play a pivotal role 
in the development of organ failure. As a mat‑
ter of fact, severe COVID ‑19 is characterized by 
an acute pneumonic reaction with diffuse alveolar 
damage, interstitial infiltrates, and microthrom‑
bi.11-13 Thus, the aim of steroid treatment in this 
setting is to reduce the burden of the inflamma‑
tory response, limiting “self ‑harm” in the body.9 
Moreover, these drugs might exert a positive ef‑
fect on hemodynamic instability, as suggested in 
the case of septic shock.14
Nevertheless, over the first months of the pan‑
demic, corticosteroid use was discouraged, or 
at least not recommended, for the treatment 
of COVID ‑19 patients. This was mostly due to 
the lack of reliable data, as explained in the first 
version of the 2020 Surviving Sepsis Campaign 
(SSC) guidelines.8 At the time of the publica‑
tion, only one small non–peer ‑reviewed study 
was available, showing that the use of methyl‑
prednisolone could reduce oxygen therapy du‑
ration and improve radiological findings.15 Thus, 
the SSC panel preferred to adopt a cautious ap‑
proach and did not recommend the routine use 
of corticosteroids in COVID ‑19 patients with re‑
spiratory failure but without acute respiratory 
distress syndrome (ARDS).8
Since then, several randomized trials have been 
published, which investigated the effects of dif‑
ferent steroids in patients with COVID ‑19. In 
the RECOVERY trial (Randomised Evaluation of 
COVID ‑19 Therapy), 6425 patients were enrolled 
and randomly assigned to receive dexamethasone 
at a dose of 6 mg once daily for 10 days (n = 2104) 
or to receive usual care alone (n = 4321).16 In 
the dexamethasone group, 28 ‑day mortality (pri‑
mary outcome) was significantly lower than in 
the control group (22.9% vs 25.7%, respective‑
ly; age ‑adjusted rate ratio [RR], 0.83; 95% confi‑
dence interval [CI], 0.75–0.93]). Moreover, in pa‑
tients under mechanical ventilation at the time 
of enrollment, dexamethasone administration 
was associated with lower mortality (29.3% and 
41.4% for dexamethasone and control groups, re‑
spectively; RR, 0.64; 95% CI, 0.51–0.81]). Simi‑
lar results were reported for patients receiving 
oxygen support without mechanical ventilation. 
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studies reported that the administration of con‑
valescent plasma with higher antibody titers in 
the early stages of COVID‑19 was associated with 
a lower 30 ‑day mortality rate.34
More recently, monoclonal antibodies have 
been developed with the aim to neutralize the 
SARS‑CoV‑2 spike protein, thus preventing vi‑
ral binding to host cells.35 Casirivimab and im‑
devimab are recombinant human immunoglobu‑
lin G1 (IgG1) monoclonal antibodies approved by 
the Food and Drug Administration for the treat‑
ment of adult and pediatric patients with mild‑
‑to ‑moderate COVID ‑19, as well as individuals 
at high risk of progression to severe COVID ‑19. 
Limited benefits have been reported for patients 
with severe COVID ‑19.36 Although the combina‑
tion of antibodies led to a reduction in viral load, 
particularly in patients who have not yet mounted 
an immune response, further research is needed 
to confirm clinical benefits.37 Another monoclo‑
nal antibody studied is bamlanivimab, a neutral‑
izing IgG1 antibody directed against the SARS‑
‑CoV ‑2 spike protein. A randomized clinical trial 
demonstrated a direct antiviral activity of bam‑
lanivimab, with a reduction in viral load and 
COVID ‑19 ‑related hospitalization.38
other therapies Several other agents have been 
also evaluated in the setting of COVID ‑19. Baric‑
itinib (a Janus kinase inhibitor) in combination 
with remdesivir has been approved for the treat‑
ment of COVID ‑19 patients who require oxygen 
or ventilatory support.39 More recent evidence 
has demonstrated its effectiveness independent‑
ly of concomitant remdesivir administration.40 
Emerging data show that baricitinib may reduce 
mortality in selected patients with severe disease 
who receive concomitant dexamethasone treat‑
ment. These findings support the results from 
randomized trials showing that baricitinib plus 
remdesivir reduced the time to recovery, even in 
patients who were on high ‑flow oxygen or non‑
invasive ventilation at baseline.25,40,41
Interferons act by modulating the immune re‑
sponse, and interferon beta was reported to in‑
hibit SARS ‑CoV ‑2 replication in vitro.42 Howev‑
er, so far, no clinical data have indicated benefits 
of using interferon beta for the treatment of se‑
vere COVID ‑19. Interferon therapy had no signif‑
icant effects on 28 ‑day mortality when compared 
with standard of care.23
Observational studies reported the use of IL ‑1 
inhibitors (eg, anakinra) to be associated with 
lower COVID ‑19 mortality.43,44 However, these 
beneficial results were not confirmed by a ran‑
domized trial in which anakinra was used in 
combination with usual care vs usual care alone 
in hospitalized patients with mild ‑to ‑moderate 
COVID ‑19.45
Anticoagulants and antithrombotics The charac‑
teristic feature of COVID ‑19 is a prothrombotic 
state with massive activation of blood coagula‑
tion, reflected by high D ‑dimer concentrations, 
required low‑flow oxygen showed significantly 
lower mortality.20 Modest results were obtained 
with the use of remdesivir among inpatients with 
nonsevere COVID ‑19.24 Finally, when adminis‑
tered with baricitinib, a Janus kinase inhibitor 
used for the treatment of rheumatoid arthritis, 
remdesivir appeared to reduce the recovery time, 
particularly among patients receiving high ‑flow 
oxygen or noninvasive ventilation.25
Anti–interleukin-6 The rationale for using anti–in‑
terleukin‑6 is the inhibition of the inflammatory 
pathway sustained by high levels of inflammato‑
ry markers (such as D ‑dimer and ferritin) as well 
as proinflammatory cytokines (including IL ‑6) as‑
sociated with severe COVID ‑19.26 Among IL ‑6 in‑
hibitors, tocilizumab has been most widely stud‑
ied in patients with COVID ‑19. A meta ‑analysis of 
8 randomized trials including patients hospital‑
ized for COVID ‑19 demonstrated lower all ‑cause 
mortality rates in tocilizumab ‑treated individu‑
als compared with those who received placebo or 
standard of care.27 Major evidence comes from 
an open ‑label trial that enrolled patients with 
suspected or confirmed COVID ‑19 with hypoxia 
and C ‑reactive protein levels higher than 75 mg/l. 
In this cohort, tocilizumab reduced the progres‑
sion to mechanical ventilation or death. More‑
over, better outcomes were reported among pa‑
tients who received concomitant corticosteroid 
treatment.16 However, these results are in con‑
trast to the findings of other trials that failed to 
demonstrate benefits for tocilizumab in terms 
of mortality and clinical symptoms.28,29 There‑
fore, expert recommendations and internation‑
al guidelines on tocilizumab vary greatly. The Na‑
tional Institute of Health recommends adding to‑
cilizumab to dexamethasone in hospitalized pa‑
tients with COVID ‑19 requiring high ‑flow oxygen 
support or noninvasive ventilation and show‑
ing evidence of clinical progression or elevated 
levels of inflammatory markers.30 A similar ap‑
proach using a combination of tocilizumab and 
corticosteroids has been suggested by the Infec‑
tious Diseases Society of America for the treat‑
ment of inpatients with COVID ‑19 presenting 
with progressive severe or critical disease and 
systemic inflammation.31
Convalescent plasma and monoclonal antibodies 
The use of convalescent plasma from patients 
who recovered from COVID ‑19 has been proposed 
to provide passive antibody ‑based immunization, 
particularly in patients with deficient antibody 
production (eg, due to treatment with anti ‑CD20 
monoclonal antibodies).32 However, despite this 
promising physiopathological insights, the avail‑
able literature does not support the use of conva‑
lescent plasma in patients with severe disease. In 
fact, randomized trials including inpatients did 
not demonstrate a clear benefit when compared 
with placebo or standard of care, either in terms 
of the length of hospital stay or in ventilation 
use.33 On the other hand, some observational 
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several experts suggested that higher heparin dos‑
es than those used for standard prophylaxis should 
be administered in severe COVID ‑19, while an in‑
termediate‑ or therapeutic ‑dose strategy could be 
considered in COVID ‑19 patients with obesity, pro‑
thrombotic conditions, or high D ‑dimer concentra‑
tions with a rapid increase during hospitalization 
(FIguRE 1).59 However, it has been shown that dose 
escalation of heparin could result in a significantly 
higher rate of clinically relevant hemorrhagic ep‑
isodes without reducing the rates of thromboem‑
bolism or mortality among hospitalized patients 
with COVID ‑19.47 Recently, the INSPIRATION trial 
(Intermediate ‑dose vs Standard Prophylactic Anti‑
coagulation and Statin vs Placebo in ICU Patients 
With COVID ‑19) showed that the use of interme‑
diate vs standard prophylactic dose of LMWH is 
not associated with a reduced risk of VTE or arte‑
rial thrombosis, requirement for extracorporeal 
membrane oxygenation, or mortality.61 The same 
was observed for major bleeding and thrombocy‑
topenia.61 Therefore, similar to thromboprophylax‑
is in hospitalized patients prior to the COVID ‑19 
pandemic, this strategy seems to reduce the risk of 
VTE but, most likely, not the risk of death.
platelet activation, formation of neutrophil extra‑
cellular traps, and generation of antiphospholipid 
antibodies, all leading to venous thromboembo‑
lism.46 Numerous reports published since the be‑
ginning of the pandemic have documented a high 
rate of venous thromboembolism (VTE), ranging 
from 17% to 69%.47-52 Currently, the mean rate 
of VTE in inpatients with COVID ‑19 is estimated 
at 9% (95% CI, 5%–13%) and 21% in the inten‑
sive care unit (ICU).53 The most common man‑
ifestation of VTE is pulmonary embolism, with 
an estimated rate of 8% (vs 3% for deep vein 
thrombosis).53-56 The risk of VTE during hospi‑
talization of COVID ‑19 patients was reported 
to increase at D ‑dimer concentrations higher 
than 2500 ng/ml (OR, 6.79; 95% CI, 2.39–19.30), 
platelet count higher than 450 000/µl (OR, 3.56; 
95% CI, 1.27–9.97), and C ‑reactive protein lev‑
els higher than 100 mg/l (OR, 2.71; 95% CI, 
1.26–5.86).57
Thromboprophylaxis with heparins, prefera‑
bly low ‑molecular ‑weight heparin (LMWH), was 
recommended in all hospitalized patients with 
COVID ‑19 unless there are absolute contraindica‑
tions.58-60 Despite the lack of high ‑quality evidence, 
FIguRE 1 Proposed algorithm of pharmacological thromboprophylaxis in hospitalized patients with COVID ‑19 
a Given the recent evidence from randomized trials published in August 2021,65,66 a therapeutic dose of LMWH could 
be considered in all not critically ill hospitalized COVID‑19 patients, especially in those with high D‑dimer levels 
Abbreviations: CRP, C ‑reactive protein; LMWH, low ‑molecular ‑weight heparin; UFH, unfractionated heparin; VTE, venous 
thromboembolism
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of VTE risk after discharge. Current studies indi‑
cate that the risk of VTE in COVID‑19 patients 
at discharge is similar to or slightly higher than 
that in the corresponding period of 2019 in pa‑
tients discharged after hospitalization for acute 
diseases. Roberts et al63 reported that the OR of 
thrombosis within 42 days from discharge in pa‑
tients with COVID ‑19 was 1.6 (95% CI, 0.6–3.1). 
In a study by Engelen et al,64 screening for VTE 
6 weeks after COVID ‑19 hospitalization revealed 
very low incidence of VTE (<1%) in a group of 146 
patients, of whom only 28% received thrombopro‑
phylaxis despite the fact that one ‑third still had 
elevated D ‑dimer levels.64 Postdischarge pharma‑
cological prophylaxis should not be longer than 
2 to 6 weeks.
The collaborative international platform trials 
ATTACC (Antithrombotic Therapy to Ameliorate 
Complications of COVID ‑19), REMAP ‑CAP (Ran‑
domized, Embedded, Multifactorial Adaptive Plat‑
form Trial for Community ‑Acquired Pneumonia), 
and ACTIV ‑4 (Anti ‑thrombotics for Adults Hos‑
pitalized With COVID ‑19) compared the safe‑
ty and efficacy of therapeutic‑ vs standard ‑dose 
thromboprophylaxis in randomly assigned hospi‑
talized patients with COVID ‑19. In August 2021, 
two studies were published which suggested that 
therapeutic daily heparin doses could be benefi‑
cial in noncritically ill patients but not in critical‑
ly ill cases.65,66 The optimal thromboprophylaxis 
protocol remains to be established.67
oxygen therapy Since the  main clinical fea‑
tures of SARS ‑CoV‑2 infection are hypoxemia 
and dyspnea,68 oxygen therapy is the corner‑
stone of the management of severe COVID ‑19 
cases (FIguRE 2).69 From a clinical perspective, as 
Major bleeding occurs in about 5% of patients 
receiving thromboprophylaxis, and the balance 
between thrombosis and bleeding should be reg‑
ularly assessed, especially if higher LMWH doses 
are administered in COVID ‑19 patients. The rate 
of major or clinically relevant nonmajor bleed‑
ing was reported at 24 per 100 person ‑months 
compared with 6.9 per 100 person ‑months in pa‑
tients receiving standard prophylactic ‑intensity 
anticoagulation.62 In critically ill patients with 
COVID ‑19, two ‑thirds of major bleeding events 
were observed in those receiving therapeutic 
anticoagulation.47 Despite platelet activation in 
COVID ‑19 patients, low ‑dose aspirin is not rec‑
ommended for thromboprophylaxis due to ele‑
vated bleeding risk unless antiplatelet agents are 
required for other indications.
Patients who experienced VTE during hospi‑
talization for COVID ‑19 should be treated with 
LMWH. Oral anticoagulants could be used dur‑
ing hospitalization in those patients with less 
severe COVID‑19 given the absence of potent 
drug‑drug interactions. Duration of anticoagu‑
lation after discharge should be individualized 
based on the assessment of VTE recurrence risk, 
but the minimal duration is 3 to 6 months. In 
COVID ‑19 patients who do not require hospital‑
ization, thromboprophylaxis should not be rou‑
tinely prescribed, except those at high risk of VTE 
(eg, patients with previous VTE, those receiving 
chemotherapy, and those with known thrombo‑
philia). Thromboprophylaxis should not be rou‑
tinely prescribed also in patients who are dis‑
charged home, as it offers benefit only in select‑
ed cases. However, these patients should under‑
go routine VTE risk assessment. The IMPROVE 
VTE score has been proposed for the assessment 
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with a reduction in the intubation rate compared 
with low ‑flow oxygen therapy, without impact 
on ICU mortality. However, it is important to 
note that the optimal management of respirato‑
ry failure in patients with COVID ‑19 should fol‑
low a structured protocol in order to anticipate 
possible complications69 and the need for me‑
chanical ventilation.81
Another therapeutic option in patients with 
respiratory failure is oxygen delivery using non‑
invasive positive pressure ventilation (NIPPV). 
By recruiting collapsed alveoli, this strategy im‑
proves gas exchange and hemodynamic perfor‑
mance.77 Moreover, it reduces the patient’s respi‑
ratory effort. In patients with COVID ‑19, NIPPV 
using a full ‑face mask (or even a dedicated helmet) 
rather than a nasal mask is suggested to reduce 
the risk of particle dispersion.69 Also, the use of 
continuous positive airway pressure is suggest‑
ed for the initial management of COVID ‑19 pa‑
tients requiring oxygen support, using the low‑
est effective pressures (eg, 5–10 cmH2O).
82 How‑
ever, the current guidelines provide a weak rec‑
ommendation on the use of NIPPV in patients 
with COVID ‑19 when high ‑flow nasal cannulas 
are not available, in the absence of urgent need 
for endotracheal intubation. The SSC panel rec‑
ommends close monitoring to avoid delays in en‑
dotracheal intubation, similar as in the manage‑
ment of patients with ARDS.9 In this context, 
Wendel Garcia et al80 showed that NIPPV failure 
and the subsequent need for invasive mechani‑
cal ventilation were associated with increased ICU 
length of stay and mortality. Thus, when a trial 
of NIPPV is adopted, close monitoring of the re‑
spiratory status and early intubation in case of 
worsening are recommended.9
Awake prone positioning Prone positioning is one 
of the therapeutic strategies currently used in 
patients with ARDS, as this technique improves 
the hemodynamic performance of both ventri‑
cles. Moreover, prone positioning of a patient 
ameliorates respiratory gas exchange by reduc‑
ing ventilation ‑perfusion mismatches.83 There‑
fore, the method has been proposed in patients 
with COVID ‑19 with the aim to reproduce these 
beneficial effects and thus avoid the need for in‑
tubation. Some interesting findings were report‑
ed.84,85 In a study by Coppo et al,86 prone position‑
ing was associated with a significant improvement 
in the ratio of arterial oxygen partial pressure to 
FiO2 compared with the supine position. Howev‑
er, more research is needed to confirm these re‑
sults. The use of prone positioning is currently 
not recommended by the SSC guideline update 
in awake nonintubated patients with COVID ‑19.9
Conclusions The  spectrum of therapies for 
COVID ‑19 has been evolving rapidly. Current‑
ly, a severity ‑based approach should be consid‑
ered. While asymptomatic or mildly symptomat‑
ic patients should receive only a symptom ‑based 
treatment and clinical monitoring, hospitalized 
the onset of dyspnea can be relatively late, dur‑
ing the first days of the disease, the patient can 
present with reduced oxygen saturation (SpO2) 
by pulse oximetry, without shortness of breath 
despite progression of the infection.70 Different 
studies estimated that the lag between symp‑
tom onset and the development of dyspnea is 7 
days on average.71,72 However, after that, the pro‑
gression to ARDS is much faster, with a median 
of 2.5 days.70-72
Typically, the respiratory pattern of COVID ‑19 
is characterized by hypoxemic respiratory failure, 
with different degrees of severity, up to an ARDS 
pattern. In this regard, the severity of COVID ‑19 
has been classified into 2 major categories:9 severe 
and critical. Severe disease is defined as COVID ‑19 
with clinical signs of pneumonia (fever, cough, 
dyspnea, tachypnea) and one of the following: 
respiratory rate higher than 30 breaths/min, se‑
vere respiratory distress, or SpO2 lower than 90% 
on room air. Critical disease refers to COVID ‑19 
with the presence of ARDS or respiratory fail‑
ure requiring ventilation, sepsis, or septic shock.
As mentioned above, ARDS is a typical compli‑
cation of COVID ‑19 progression, with numerous 
features overlapping those of ARDS from other 
causes, such as a reduction in lung compliance.73 
However, compared with ARDS from other causes, 
the risk of barotrauma seems slightly increased.74
Peripheral oxygen saturation Peripheral oxygen 
saturation monitoring is crucial in the man‑
agement of COVID ‑19 patients. At the onset of 
the disease, plethysmography allows clinicians 
to noninvasively detect deterioration in respira‑
tory exchange, even in patients with mild symp‑
toms.75,76 In fact, the first update of the SSC 
guidelines on the management of patients with 
COVID ‑19 suggested starting supplemental oxy‑
gen administration when SpO2 is lower than 92% 
and recommended supplemental oxygen admin‑
istration when SpO2 is lower than 90%. The rec‑
ommended target is SpO2 not higher than 96%.
9
oxygen administration The first ‑line therapy in pa‑
tients with acute respiratory failure is low ‑flow ox‑
ygen administration via a nasal cannula or, more 
frequently, via a face mask with a known fraction 
of inspired oxygen (FiO2).
69 The Novara ‑COVID 
Score, one of the earliest validated prognostic 
scores in the setting of COVID ‑19, has been de‑
signed to evaluate the patient’s response to ox‑
ygen therapy administered at a FiO2 of 50%.
5,6
When low ‑flow oxygen fails to significantly im‑
prove SpO2 and gas exchanges, oxygen therapy us‑
ing a high ‑flow nasal cannula is recommended.9 
This device allows the administration of high flows 
of humidified oxygen (up to 70 l/min), with a FiO2 
of up to 100%.77-79 Recent studies on COVID ‑19 
patients have yielded interesting results. Wen‑
del Garcia et al80 investigated 351 patients with 
COVID ‑19 and reported that an early trial of high‑
‑flow nasal cannula might be the most balanced 
initial respiratory support, as it was associated 
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patients with fully symptomatic disease could be 
candidates for antiviral treatment. Corticoste‑
roid administration should be reserved for more 
severe cases, particularly those with respiratory 
failure or ARDS. Since the main clinical features 
of COVID ‑19 are hypoxemia and dyspnea, oxy‑
gen therapy remains the mainstay of treatment 
in patients with severe disease.
Current challenges in the  treatment of 
COVID ‑19 include the need to determine the ef‑
fectiveness of convalescent plasma and monoclo‑
nal antibodies as well as to identify the optimal 
target and timing of anticoagulation.
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